Delta-opioid receptors as targets for migraine therapy
- 1 June 2016
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Neurology
- Vol. 29 (3), 314-319
- https://doi.org/10.1097/wco.0000000000000311
Abstract
The purpose of this review is to contrast the properties of the δ-opioid receptor with those of the μ-opioid receptor, which is the primary target of most currently available opioid analgesics. We also discuss preclinical evidence that indicates the potential efficacy of δ-opioid receptor agonists as migraine therapy.The use of currently available opioid analgesics is highly problematic for patients with migraine. Delta-opioid receptors have key differences from μ receptors; these differences make the δ receptor an attractive therapeutic target for migraine. Delta-opioid receptors are expressed in both the peripheral and central nervous system in anatomical regions and cell types that are believed to play a role in migraine. Delta-receptor agonists have also shown promising effects in multiple migraine models, including nitroglycerin evoked hyperalgesia and conditioned place aversion, and cortical spreading depression. Evidence from animal models indicates that activation of δ receptors is less likely to cause tolerance and dependence, and less likely to cause hyperalgesia. In addition, δ receptors may have antidepressant and anxiolytic properties that are distinct from those of μ receptors. In human studies investigating other conditions, δ-receptor agonists have been generally safe and well tolerated.Delta-opioid receptor agonists have promising potential as acute and/or preventive migraine therapies, without the problems associated with currently used opioid analgesics.Keywords
This publication has 49 references indexed in Scilit:
- Rates of opioid misuse, abuse, and addiction in chronic painPain, 2015
- The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention WorkshopAnnals of Internal Medicine, 2015
- Opioids for chronic noncancer painNeurology, 2014
- Non-peptidic δ opioid receptor agonists and antagonists (2000 – 2012)Expert Opinion on Therapeutic Patents, 2013
- Delta and Kappa Opioid Receptors as Suitable Drug Targets for PainThe Clinical Journal of Pain, 2010
- Dissociation of the Opioid Receptor Mechanisms that Control Mechanical and Heat PainCell, 2009
- Impact of Recent Prior Opioid Use on Rizatriptan Efficacy. A Post Hoc Pooled AnalysisHeadache: The Journal of Head and Face Pain, 2009
- Excessive acute migraine medication use and migraine progressionNeurology, 2008
- Acute Migraine Medications and Evolution From Episodic to Chronic Migraine: A Longitudinal Population‐Based StudyHeadache: The Journal of Head and Face Pain, 2008
- Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: An in situ hybridization studyJournal of Comparative Neurology, 1994